American Society of Clinical Psychopharmacology (ASCP)

The American Society of Clinical Psychopharmacology (ASCP) was founded in 1992 to advance the science and practice of clinical psychopharmacology. Its over 900 members are physicians who study and practice psychopharmacology, as well as doctoral level investigators of clinical psychopharmacology or of pharmacology. ASCP members are advocates for clinical psychopharmacology and for clinical research.

Mission:
The mission of the American Society of Clinical Psychopharmacology is to advance the science, practice, and education of clinical psychopharmacology, and to improve the health and well-being of their patients.

Vision:
The ASCP will be the leading source of innovation in research, education and practice for psychopharmacology and other treatment modalities to improve the lives of those with psychiatric disorders.

ASCP Goals:
• Enhance the development of cutting-edge research in the field of clinical psychopharmacology and related fields by providing investigators and clinicians the opportunity to engage in discussion, education, and dissemination of research findings and new methodologies.
• Enhance ASCP’s role as the preeminent leader in innovative education in clinical psychopharmacology and related fields to foster the development of best practices, new treatments, curricula, and training for all career levels.
• Increase the leadership, membership, and participation of all underrepresented groups in the Society by cultivating inclusion to ensure that all members, meeting attendees, and collaborators feel welcomed, empowered, and valued.
• Develop initiatives, partnerships, and collaborations that bring together leading experts from diverse settings - including academic, industry, clinical, and government - to advance the field of psychopharmacology.